Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
Northwestern University
Barbara Ann Karmanos Cancer Institute
Fred Hutchinson Cancer Center
Roswell Park Cancer Institute
Northside Hospital, Inc.